Compare Abbott Laboratories (ABT) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Becton Dickinson and Co — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Becton Dickinson and Co trades at $151 (market cap $43.07B). The key difference: Abbott Laboratories is far larger — about 3.9× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| ABT | BDX | |
|---|---|---|
Market Cap | $166.94B | $43.07B |
Sector | Health | Health |
52-Week High | $136.62 | $185.39 |
52-Week Low | $82.57 | $135.49 |
Enterprise Value | $193.69B | $59.53B |
Dividend Yield | 2.63% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BDX trades at $156.30, down 1.13% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations for Q1 2026, and the company maintains stable revenue growth, reaching $21.84B in 2025. Positive news highlights innovation in medical technology and dividend reliability, supporting a mixed but leaning positive analyst view.
Outlook is cautiously optimistic with a consensus price target of $172.33 offering ~10% upside. Risks include hospital spending caution and reimbursement uncertainty, but strong cash flow and product launches provide growth catalysts. The stock presents a balanced opportunity for dividend-focused investors amid moderate volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
